Preserved antigen-specific immune response in patients with multiple sclerosis responding to IFNβ-therapy

PLoS One. 2013 Nov 5;8(11):e78532. doi: 10.1371/journal.pone.0078532. eCollection 2013.

Abstract

Background: Interferon-beta (IFNβ) regulates the expression of a complex set of pro- as well as anti-inflammatory genes. In cohorts of MS patients unstratified for therapeutic response to IFNβ, normal vaccine-specific immune responses have been observed. Data capturing antigen-specific immune responses in cohorts of subjects defined by response to IFNβ-therapy are not available.

Objective: To assess antigen-specific immune responses in a cohort of MS patients responding clinically and radiologically to IFNβ.

Methods: In 26 MS patients, clinical and MRI disease activity were assessed before and under treatment with IFNβ. Humoral and cellular immune response to influenza vaccine was prospectively characterized in these individuals, and 33 healthy controls by influenza-specific Enzyme-Linked Immunosorbent Assay (ELISA) and Enzyme Linked Immuno Spot Technique (ELISPOT).

Results: Related to pre-treatment disease activity, IFNβ reduced clinical and radiological MS disease-activity. Following influenza vaccination, frequencies of influenza-specific T cells and concentrations of anti-influenza A and B IgM and IgG increased comparably in MS-patients and in healthy controls.

Conclusions: By showing in a cohort of MS-patients responding to IFNβ vaccine-specific immune responses comparable to controls, this study indicates that antigen-specific immune responses can be preserved under successful IFNβ-therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antibodies, Viral / blood*
  • Antigens, Viral / blood*
  • Case-Control Studies
  • Enzyme-Linked Immunosorbent Assay
  • Enzyme-Linked Immunospot Assay
  • Female
  • Humans
  • Immunity, Cellular / drug effects
  • Immunity, Humoral / drug effects
  • Immunoglobulin G / blood
  • Immunoglobulin M / blood
  • Influenza Vaccines / administration & dosage*
  • Influenza, Human / blood
  • Influenza, Human / immunology
  • Influenza, Human / prevention & control*
  • Interferon-beta / therapeutic use*
  • Male
  • Middle Aged
  • Multiple Sclerosis / blood
  • Multiple Sclerosis / drug therapy
  • Multiple Sclerosis / immunology*
  • Multiple Sclerosis / pathology
  • Orthomyxoviridae / immunology*
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / immunology
  • T-Lymphocytes / pathology
  • Vaccination

Substances

  • Antibodies, Viral
  • Antigens, Viral
  • Immunoglobulin G
  • Immunoglobulin M
  • Influenza Vaccines
  • Interferon-beta

Grants and funding

This investigator initiated and sponsored study was supported by Novartis AG, Basel, Switzerland. C. Hess is supported by the Swiss National Science Foundation (PP00B-114850 and 31003A_135677), and L. Kappos and M. Mehling by the Swiss MS Society. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.